FDA's Opioid REMS Review Puts Brakes On Mandatory Education Push
This article was originally published in The Pink Sheet Daily
Executive Summary
Requiring training and certification for extended-release opioids would involve at least 320,000 prescribers and impact 21 million outpatient prescriptions, reviewers note in a briefing memo that is more skeptical of the mandatory approach than FDA's leadership has been.